Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

7.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
7.5K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

2.6K
2.6K
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

12.4K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
12.4K
RNA Splicing01:32

RNA Splicing

53.3K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
53.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mutation of TGFβ-RII eliminates NSAID cancer chemoprevention.

Oncotarget·2018
Same author

Loss of miR-204 expression is a key event in melanoma.

Molecular cancer·2018
Same author

Retraction for Melillo et al., "Critical Role of the HMGI(Y) Proteins in Adipocytic Cell Growth and Differentiation".

Molecular and cellular biology·2018
Same author

Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia.

Oncotarget·2018
Same author

Long noncoding RNAs: Undeciphered cellular codes encrypting keys of colorectal cancer pathogenesis.

Cancer letters·2018
Same author

The role of MicroRNAs in human cancer.

Signal transduction and targeted therapy·2017

Related Experiment Video

Updated: May 4, 2026

Laser-capture Microdissection of Human Prostatic Epithelium for RNA Analysis
07:42

Laser-capture Microdissection of Human Prostatic Epithelium for RNA Analysis

Published on: November 26, 2015

12.7K

Long noncoding RNA in prostate, bladder, and kidney cancer.

Elena S Martens-Uzunova1, René Böttcher2, Carlo M Croce3

  • 1Department of Urology, Erasmus Medical Centre, Rotterdam, The Netherlands.

European Urology
|December 31, 2013
PubMed
Summary

Long noncoding RNAs (lncRNAs) are crucial in urologic cancers like prostate, bladder, and kidney. These molecules show promise as noninvasive biomarkers and potential therapeutic targets for cancer detection and treatment.

Keywords:
Beckwith-Wiedemann syndromeBladder cancerKidney cancerLong noncoding RNAProstate cancerRenal cell carcinomaUrothelial carcinomaWilms tumourlncRNA

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

5.8K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.3K

Related Experiment Videos

Last Updated: May 4, 2026

Laser-capture Microdissection of Human Prostatic Epithelium for RNA Analysis
07:42

Laser-capture Microdissection of Human Prostatic Epithelium for RNA Analysis

Published on: November 26, 2015

12.7K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

5.8K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.3K

Area of Science:

  • Molecular Biology
  • Genomics
  • Oncology

Background:

  • Genomic regions lacking protein-coding potential produce numerous noncoding RNAs (ncRNAs).
  • Long noncoding RNAs (lncRNAs) are increasingly recognized for their roles in cellular processes.
  • Evidence suggests lncRNAs are frequently altered in human urologic cancers.

Purpose of the Study:

  • To review the biology and implications of lncRNAs in prostate, bladder, and kidney cancer.
  • To explore the potential of lncRNAs as biomarkers and therapeutic targets in urologic malignancies.

Main Methods:

  • Systematic literature search of the PubMed database.
  • Inclusion of English-language articles using specific MeSH terms related to lncRNAs and urologic cancers.

Main Results:

  • Summarized current knowledge on lncRNA systematics, biology, and function in prostate, kidney, and bladder cancers.
  • Discussed the utility of lncRNAs as novel biomarkers and therapeutic targets.
  • Highlighted challenges and future perspectives in lncRNA research.

Conclusions:

  • lncRNAs regulate gene expression critical for cell growth, proliferation, differentiation, and survival.
  • Dysfunctional lncRNAs contribute to tumor formation, progression, and metastasis in urologic cancers.
  • lncRNAs offer potential as noninvasive tumor markers and future therapeutic targets, warranting further research into their biologic functions.